U.S. Building Stock News

If you are wondering whether Day One Biopharmaceuticals' current share price lines up with its underlying worth, you are not alone. The stock most recently closed at US$10.60, with a 7 day return of 10% decline, a 30 day return of 5% decline, gains of 19.8% year to date and 17% over the past year, while the 3 year return sits at 43.4% decline. Recent news around Day One has largely focused on its development stage oncology pipeline and ongoing progress in clinical programs, which can...

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...

In late February 2026, Pinnacle Financial Partners was highlighted by hedge funds as one of the ten leading banking stocks, with analysts citing stronger capital levels and higher earnings forecasts following its fourth-quarter results and management’s confident outlook. A few days later, hotter-than-expected inflation data and rising worries about credit risk in areas like private credit and leveraged loans led investors to reassess regional banks’ risk profiles, putting pressure on...

If you are wondering whether Kaiser Aluminum's current share price lines up with its underlying worth, this article walks through the key signals you will want to weigh. The stock last closed at US$130.14, with returns of 0.9% over 7 days, 6.1% over 30 days, 8.2% year to date, 90.5% over 1 year, 74.0% over 3 years, and 36.6% over 5 years. This performance sets an important backdrop for any value check. Recent coverage around Kaiser Aluminum has focused on how investors view its role within...

If you are looking at Acadia Realty Trust and wondering whether the current share price gives you good value, this article will walk through what the numbers are actually saying. The stock last closed at US$20.92, with returns of 3.2% over 7 days, 4.5% over 30 days, 1.4% year to date, a 5.6% decline over 1 year, 62.7% over 3 years and 30.0% over 5 years. Together, these figures provide a wide mix of recent and longer term outcomes to think about. Recent moves in Acadia Realty Trust's share...

Perimeter Solutions (NYSE:PRM) is dealing with operational and safety issues at its Sauget P2S5 facility that have led to reduced production and ongoing litigation as it seeks to take control of the site. The company has recently closed a sizeable acquisition while shifting more of its portfolio toward fixed and recurring contracts to support more consistent earnings. These developments affect a key production asset and the structure of Perimeter Solutions' revenue, with potential...

In recent weeks, UGI Utilities has begun additional natural gas system upgrades in Lancaster and implemented higher purchased gas cost rates, while its proposal for a US$99.40 million annual distribution rate increase has been temporarily suspended by the Pennsylvania Public Utility Commission for further review. Together, these infrastructure investments, customer bill impacts, and regulatory oversight highlight how UGI’s earnings profile is closely tied to state-level rate decisions and...

IDACORP, Inc. recently reported its full-year 2025 results, with sales of US$1.81 billion, revenue of US$1.81 billion, and net income rising to US$323.47 million, alongside higher basic and diluted earnings per share from continuing operations compared with 2024. At the same time, the company issued 2026 earnings guidance of US$6.25 to US$6.45 per diluted share, highlighting management’s expectations while signaling limited use of additional tax credits under Idaho’s regulatory...

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis, a chronic nasal disease. The FDA also accepted garetosmab for Priority Review for treating fibrodysplasia ossificans progressiva, a rare and serious genetic disorder. For you as an investor, these decisions highlight where Regeneron focuses its efforts: targeted biologic therapies in areas with limited existing options. Dupixent already sits at the center...

If you are wondering whether Altria Group's share price still lines up with its underlying value, this article walks through the key numbers that matter before you make any big calls. Altria Group recently closed at US$69.04, with returns of 2.2% over 7 days, 11.4% over 30 days, 20.5% year to date, 32.5% over 1 year, 88.4% over 3 years and 125.9% over 5 years. These figures raise fair questions about how the current price compares to estimated fair value. Recent news coverage has focused on...

If you are wondering whether Rayonier's current share price reflects its underlying value, this article will walk through what the numbers are actually saying. At a last close of US$21.49, Rayonier's shareholders have seen a 5.2% decline over the past week and a 5.5% decline over 30 days. The stock is also lower over 1 year, 3 years, and 5 years. These recent returns have put more attention on how Rayonier is being valued and what expectations are built into the current price. With the share...

If you are wondering whether Newmark Group's share price reflects its underlying worth today, you are not alone. This article is set up to help you frame that question clearly. The stock recently closed at US$14.52, with returns of a 3.8% decline over 7 days, 18.6% decline over 30 days, 14.4% decline year to date and 0.2% decline over the past year, while the 3 year and 5 year returns sit at 89.2% and 50.1% respectively. These moves have put valuation back in focus for Newmark Group...

If you are wondering whether SS&C Technologies Holdings is offering fair value at its current price, or if the market is mispricing it, this article walks through the key numbers that matter for you as a shareholder or potential investor. The stock last closed at US$75.29, with a recent 5.5% gain over 7 days sitting against a 12.2% decline year to date and a 14.4% decline over the past year. The 3 year and 5 year returns are 31.4% and 21.6% respectively. These mixed returns sit alongside an...

On 19 February 2026, Laureate Education reported fourth-quarter 2025 results showing higher sales and earnings per share than a year earlier, issued first-quarter and full-year 2026 revenue guidance, and disclosed completion of a US$218.89 million buyback under its existing program. On the same day, the company also expanded its capital return plans by increasing its share repurchase authorization to US$400 million, signaling management’s confidence in its financial capacity while it...

Honest Company (HNST) has drawn fresh attention after reporting full year 2025 results that show lower sales and a wider net loss, along with new 2026 guidance and a US$25 million share repurchase program. See our latest analysis for Honest Company. At a share price of US$2.80, recent moves have been mixed, with a strong 7 day share price return of 23.35% and a 30 day share price return of 13.36%. However, a 1 year total shareholder return decline of 48.15% suggests longer term holders have...

Syndax Pharmaceuticals secured its third FDA approval within a year, following the launches of Revuforj and Niktimvo. The company is rapidly shifting into a commercial-stage model with revenues now coming from multiple newly approved therapies. Pivotal clinical trials are in progress that could support label expansions and additional indications. Syndax Pharmaceuticals, NasdaqGS:SNDX, is moving from a pure R&D story to an active commercial player, supported by three FDA approved therapies...

Flywire appointed Patrick Blanc as Chief Technology Officer as part of a leadership realignment focused on AI driven product development. Blanc brings payments technology experience from senior roles at Ingenico, Visa, and PayPal. David King moved into the role of Chief Product Officer and Co President of Global Education to support Flywire's product and sector focus. For investors tracking NasdaqGS:FLYW, this leadership reshuffle comes with the stock recently closing at $12.31 and showing...

Republic Airways Holdings (RJET) has drawn fresh attention after recent trading, with the stock up 1.7% on the day and double digit gains over the past month and the past 3 months. See our latest analysis for Republic Airways Holdings. With the latest share price at $21.73, a 1 day share price return of 1.7% builds on a 7 day gain of 10.0% and a 30 day share price return of 26.3%. The year to date move of 10.8% suggests momentum has picked up recently compared with earlier in the year. If...

If you are wondering whether SailPoint is starting to look interesting on price, this is a good moment to step back and ask what its current market value really reflects. The stock last closed at US$14.10, with returns of 0.6% decline over 7 days, 10.1% decline over 30 days, 25.6% decline year to date and 41.2% decline over the past year. These moves can change how investors think about both potential upside and risk. Recent news around SailPoint has focused on its role in identity security...

If you are wondering whether Applied Optoelectronics is still attractively priced after its big run, this article will help you weigh what you are paying against what you are getting. The stock recently closed at US$84.23, with returns of 63% over 7 days, 93.1% over 30 days, 112.7% year to date and 285.3% over 1 year, while the 3 year return is very large and the 5 year return sits at 947%. Recent headlines have focused on Applied Optoelectronics as a key name in optical networking and data...

Chewy appointed Christopher S. Deppe as its new Chief Financial Officer after an extensive search. Deppe previously served as Head of Corporate and Commercial Finance at Chewy and held senior leadership roles at Amazon. This is Chewy’s first major permanent executive appointment following an interim period in the finance role. For investors watching NYSE:CHWY, a permanent CFO is a key piece of the puzzle. Chewy’s shares recently closed at $27.42, with a 3.7% gain over the past week but...

If you are wondering whether Qorvo at around US$82.90 still offers value or is pricing in too much optimism already, you are not alone. The stock has returned 0.8% over the last 7 days and 6.1% over the last 30 days, while the year to date return sits at a 3.9% decline and the 1 year return is 14.0%. This compares to a 19.3% decline over 3 years and a 51.6% decline over 5 years. Recent coverage of Qorvo has focused on its role within the semiconductor sector and how investor expectations are...

Recent Share Performance Snapshot Prestige Consumer Healthcare (PBH) has seen mixed share performance recently, with a 1 day return of roughly a 1.3% decline, a flat result over the past week, and gains over the month and past 3 months. Over longer periods the picture is split, with a 13.2% gain year to date and a 14.9% total return over 3 years, set against an 18.2% total return decline over the past year. See our latest analysis for Prestige Consumer Healthcare. At a share price of $69.30,...